Ratings Surperformance

Trader
Investor
Global
Quality
ESG MSCI
AA

Ratings ESG MSCI

Ratings Biogen Inc.: Strengths and Weaknesses

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • The company has a good ESG score relative to its sector, according to MSCI.
Highlights: Biogen Inc.
  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • The company has a low valuation given the cash flows generated by its activity.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Sales forecast by analysts have been recently revised upwards.
  • Over the past four months, analysts' average price target has been revised upwards significantly.
  • The opinion of analysts covering the stock has improved over the past four months.
Weaknesses: Biogen Inc.
  • The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • Most analysts agree on a negative opinion with regard to the stock. Indeed, the average consensus issues recommendations to underperform or sell.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Rating Financials

Biogen Inc. SectorUnited States
Fundamentals
Growth
Revenue growth
EPS growth
FCF growth
Profitability
EBITDA Margin
EBIT Margin
Net Margin
Capital Efficiency
ROA
ROCE
ROE
Financial Health
Gearing
Leverage
Capital Intensity
Balance sheet growth
Long Term balance sheet growth
Long term revenue growth
Long term EPS growth
More ratings

Rating Valuation

Biogen Inc. SectorUnited States
Global Valuation
Enterprise value
EV/Revenue
EV/EBITDA
EV/FCF
Equity Valuation
P/E
PBR
Dividend Yield-
EV/EBIT
CAPEX/Revenue
More ratings

Rating Consensus

Biogen Inc. SectorUnited States
Consensus
Analysts' buy/sell recommendations
Analysts' recommendations evolution (1 year)
Analysts' recommendations evolution (4 months)
Analysts' target price
Analysts' target price evolution (1 year)
Analysts' target price evolution (4 months)
Analysts' recommendations evolution (7 days)
Target Price evolution (7 days)
More ratings

Rating Business Predictability

Biogen Inc. SectorUnited States
Visibility
Analysts' coverage
Financial estimates divergence
Analysts' recommendations divergence
Analysts' Target price divergence
Surprise rates

Rating Revisions

Biogen Inc. SectorUnited States
Financial revisions
Revenue revisions (1 year)
Revenue revisions (4 months)
EPS revisions (1 year)
EPS revisions (4 months)
EPS revisions (7 days)
Revenue revisions (7 days)
More ratings

Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
26.6B
AA
73.7B
A
58.94B
AA
54.7B
AA
51.57B
BBB
20.25B
AAA
20.13B
AA
16.58B
CCC
14.19B -
BB
- -
14.02B -
BBB
- - -
Average 35.07B
A
Weighted average by Cap.
A
See all sector ratings